Softhale has successfully achieved certification of its’ quality management system for medical devices. ISO 13485 is the medical industry's optimal, internationally agreed, medical device standard. It ensures that medical devices meet the proper regulatory compliance laws and customer needs.
Laurence brings large and small size healthcare company and investment firm experience, supporting executive missions to secure the growth path and related corporate financing. Laurence previously worked for Hoffmann-La Roche, Credit-Suisse and is Partner at Cukierman & Co. Life Sciences.
A series B fund raising was successfully closed with existing investors led by New Rhein Healthcare Investors LLC in a low double digit mEUR range. The funds will finance near-term R&D activities for our lead compounds entering into the clinic, the growth of our team and expertise to develop our portfolio of branded high-end products as well as the expansion of our collaborations evaluating the span of our technology platform.
Iain has a strong scientific background and significant technical project management experience, leading multiple cross-functional teams in high value, first-to-file opportunities for generic combination drug products in varied inhaled dosage forms. Iain joins Softhale from Teva (formerly Actavis) and is ex-Novartis and ex-Sanofi.
We are delighted to welcome Mr. Nevan Charles Elam, J.D., on our Board. He has a rich background in management, operations, consulting, finance, and corporate law in combination with long term experiences in executive roles in pharmaceutical and medical device companies.
Steven is an engineer and an expert in combination product development in the field of orally inhaled drug products for both branded and generic submissions. He brings over 20 years of experience, most recently from Teva (formerly Actavis), PA Consulting, Novartis and IVAX.
With almost 15 years of experience Isabel comes from Chiesi, Hovione and Pfizer where she was the Lead Senior Scientist and Project Coordinator of more than 20 projects related with the development and manufacturing of both generic and NCE orally inhaled drug products.
Dr. Jan-Torsten Tews joins Softhale NV as CEO. Dr. Tews joins from Sandoz, where he led the Global Respiratory Business of Novartis's Gx Division. Prior to Sandoz, he was Head of Respiratory Europe at Teva Pharmaceuticals and had worked for GlaxoSmithKline, Germany, in a broad range of leadership positions across Marketing, Sales and Health Outcomes. Focused on the treatment of asthma and COPD over 20 years and from different perspectives, Dr. Tews brings a vast experience in development, marketing and sales of inhalation products.